Leaked EU Document Lays Out Major Evaluation Of EU Drug Pricing 25/05/2016 by William New, Intellectual Property Watch 7 Comments The 28 European Union member governments are preparing to request the European Commission to conduct an in-depth evaluation of the availability and affordability of EU medicinal products that could lead to changes in R&D and pricing models. An apparent first-of-its-kind, the assessment would look at market and data exclusivity, supplementary protection certificates, and intellectual property issues, according to an alleged copy of the draft Council conclusions obtained by Intellectual Property Watch.
Innovation And Access: Fission Or Fusion? Interview With Tim Wilsdon, CRA Vice President 25/05/2016 by Guest contributor for Intellectual Property Watch Leave a Comment In the light of the UN High-Level Panel on Access to Medicines, this series of sponsored articles challenges experts to give their views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. The views expressed in the articles are those of the authors. Below is an interview with Tim Wilsdon, Vice President, CRA.
Unaffordable Medicines Now Global Issue; System Needs Change, Panellists Say 25/05/2016 by Catherine Saez, Intellectual Property Watch 5 Comments At a side event to this week’s annual World Health Assembly, a member of the Netherlands Ministry of Health delivered an unexpected speech on access to medicines, calling for more clarity in the setting of medicine prices, looking inside and outside of the patent system for solutions, and praising de-linkage. Other panellists viewed partnerships as a key ingredient to fill research and development gaps. And a representative from the Gates Foundation advised against a hasty switch to new system.
Guilty As Charged? Pakistan And The Special 301 Reports 23/05/2016 by Intellectual Property Watch Leave a Comment Owais Hassan Shaikh writes: According to the section of US law on Special 301 reports, a country may be considered a priority foreign country even when it is fully compliant with the WTO Agreement on the Trade-Related Aspects of Intellectual Property Rights (TRIPS), the main multilateral agreement on IP rights today. Hence, this legislation and the determinations made in the Special 301 reports prioritize protection of commercial interests of the US nationals.
Innovation And Access: Fission Or Fusion? Interview with David Taylor, Professor of Pharmaceutical and Public Health Policy, University College London, UK 18/05/2016 by Guest contributor for Intellectual Property Watch Leave a Comment In the light of the UN High-Level Panel on Access to Medicines, this series of sponsored articles challenges experts to give their views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. The views expressed in the articles are those of the authors. Below is an interview with David Taylor, Professor of Pharmaceutical and Public Health Policy, University College London, UK.
Biggest World Health Assembly Ever Kicks Off Next Week With A Loaded Agenda 18/05/2016 by Catherine Saez and William New, Intellectual Property Watch 3 Comments Next week the annual assembly of World Health Organization member states will take place with a heavy agenda and its largest attendance ever. The lack of new antibiotics to address bacterial resistance, global shortages of vaccines and medicines, the fight against substandard drugs, and a framework to guard against undue influence of outside actors on the work of the WHO are part of a picture where there is an increasing blur between developed and developing countries in terms of access to medicines. And then there is the matter of electing a new WHO director general.
WHO Seeks USD160m For Role Change To Coordinate Global Emergencies 18/05/2016 by William New, Intellectual Property Watch 1 Comment At its annual Assembly next week, the World Health Organization will seek member state approval of US$160 million over two years to establish its role as a global coordinator for health emergencies. Image Credits: UN
India Releases New Intellectual Property Policy; Reactions Building 13/05/2016 by William New and Patralekha Chatterjee for Intellectual Property Watch 4 Comments The Indian government today released its long-awaited new intellectual property policy, and preliminary reactions appear to be that it caters to international pressures while attempting to provide a national focus. A more careful reading with reactions will follow.
US President Signs New Trade Secrets Law 12/05/2016 by William New, Intellectual Property Watch Leave a Comment US President Barack Obama yesterday signed into law a measure aimed at strengthening trade secret protection including by allowing federal courts to hear cases involving trade secret theft.
Public Health Advocates Urge WHO Action On Alternative R&D Financing 12/05/2016 by William New, Intellectual Property Watch 2 Comments Public health advocates last week told World Health Organization delegates they must act quickly to save the lives of poor populations suffering from less common diseases for which there is no research and development funding. Nongovernmental organisations showed up to a WHO meeting on the issue to urge on delegates, even holding a public demonstration in front of the UN, but there was concern afterward at the little progress made.